



Express Mail Laboratory. EV 956 464 888 US Dated: November 30, 2007

Used in Lieu of PTO/SB/08A/B  
(Based on PTO 10-07 version)

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/773,773-Conf. #8486
				Filing Date	February 5, 2004
				First Named Inventor	Timothy F. KOWALIK
				Art Unit	1635
				Examiner Name	D. H. Shin
Sheet	1	of	1	Attorney Docket Number	UMY-079

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1	5,767,102	06-16-1998	Draper et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Grzelinski, Marius et al., "RNA Interference-Mediated Gene Silencing of Pleiotrophin Through Polyethylenimine-Complexed Small Interfering RNAs In Vivo Exerts Antitumor Effects in Glioblastoma Xenografts," <i>Human Gene Therapy</i> , Vol. 17:751-766 (2006)	
	C2	Hu-Lieskovan, Siwen et al., "Sequence-Specific Knockdown of EWS-FLI1 by Targeted, Nonviral Delivery of Small Interfering RNA Inhibits Tumor Growth in a Murine Model of Metastatic Ewing's Sarcoma," <i>Cancer Research</i> , Vol. 65(19):8984-8992 (2005)	
	C3	Li, Bao-jian et al., "Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque," <i>Nature Medicine</i> , Vol. 11(9):944-951 (2005)	
	C4	Reich, Samuel J. et al., "Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model," <i>Molecular Vision</i> , Vol. 9:210-216 (2003)	
	C5	Soutschek, Jürgen et al., "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs," <i>Nature</i> , Vol. 432:173-178 (2004)	
	C6	Tan, P. H. et al., "Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat," <i>Gene Therapy</i> , Vol. 12:59-66 (2005)	
	C7	Thakker, Deepak R. et al., "Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral interference," <i>PNAS</i> , Vol. 101(49):17270-17275 (2004)	
	C8	Zhang, Yingjie et al., "Engineering Mucosal RNA Interference in Vivo," <i>Molecular Therapy</i> , Vol. 14(3):336-342 (2006)	
	C9	Zimmermann, Tracy S. et al., "RNAi-mediated gene silencing in non-human primates," <i>Nature</i> , Vol. 441:111-114 (2006)	
	C10	de Smet, Marc D. et al., "Fomivirsin-a phosphorothioate oligonucleotide for the treatment of CMV Retinitis," <i>Ocular Immunology and Inflammation</i> , Vol. 7, No. 3-4, p. 189-198 (1999)	
	C11	Ambion, Inc. "Designing a Better siRNA," <i>TechNotes</i> Vol. 10, No. 4, p. 1-3 (2003)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--